Table 14.
Representative medical countermeasures for treating Zika virus infection
| Classification | Name | Platform/Strategy | Stage | Efficacy/Benefic | References |
|---|---|---|---|---|---|
| Vaccines | Inactivated vaccines | Formalin-inactivated Zika virus | Clinical | Safe and immunogenic in humans | 774 |
| GLS5700 | DNA vaccine encoding prM-E sequence of African and Asian/American strains | Clinical | Immunogenic in mice and NHPs | 775 | |
| VRC5288/VRC5283 | DNA vaccine encoding chimeric prM-E or prM-E | Clinical | Safe, tolerate and immunogenic | 776,777 | |
| mRNA vaccine | Non-self-amplified mRNA and nonintegrated vectors | Preclinical | Protect mice and NHPs | 778,779 | |
| Self-amplified mRNA | Preclinical | Immunogenic in mice | 780 | ||
| MeV-prM-ENV | Measles virus vector expressing prM-ENV | Clinical | Immunogenic in mice and NHPs | 781,782 | |
| RHAd52-prM-ENV | RHAd52 vector expressing prM-ENV | Preclinical | Immunogenic in NHPs | 774 | |
| Antibodies | ZIKV-117 | Human monoclonal antibody targeting a unique quaternary epitope on the E protein | Preclinical | Broadly neutralized ZIKV African and Asian-American lineages and effective in mice | 784 |
| ZKA78 | Human monoclonal antibody targeting EDIII | Preclinical | Protect mice | 785 | |
| Small molecular drugs | BCX 4430 | RdRp inhibitor | Preclinical | Effective in mice | 789 |
The following acronyms are used: membrane and envelope proteins (prM-E); rhesus monkey adenovirus serotype 52 (RHAd52); envelop protein domain III(EDIII); RNA dependent RNA polymerase (RdRp); nonhuman primates (NHPs)